loadpatents
name:-0.042324066162109
name:-0.010356903076172
name:-0.0093050003051758
Huang; Cai Gu Patent Filings

Huang; Cai Gu

Patent Applications and Registrations

Patent applications and USPTO patent grants for Huang; Cai Gu.The latest application filed is for "formulation of nanoantibody based drugs and a method for treating thrombotic thrombocytopenic purpura by inhalation".

Company Profile
22.10.94
  • Huang; Cai Gu - Shrewsbury MA
  • Huang; Cai Gu - Sudbury MA
  • Huang; Cai Gu - Guangzhou CN
  • Huang; Cai Gu - Guangzhou city CN
  • Huang; Cai Gu - Shang Gao CN
  • Huang; Cai Gu - Northbrough MA
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Inhalation atomizer comprising a blocking function and a counter
Grant 11,369,760 - Huang June 28, 2
2022-06-28
Formulation of tocilizumab and method for treating COVID-19 by inhalation
Grant 11,365,248 - Huang , et al. June 21, 2
2022-06-21
Liposome formulation of fluticasone furoate and method of preparation
Grant 11,304,901 - Huang , et al. April 19, 2
2022-04-19
Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
Grant 11,304,897 - Huang , et al. April 19, 2
2022-04-19
Formulation Of Nanoantibody Based Drugs And A Method For Treating Thrombotic Thrombocytopenic Purpura By Inhalation
App 20220064328 - Huang; Cai Gu ;   et al.
2022-03-03
Preparation Of A Pharmaceutical Composition Of Olodaterol And Budesonide
App 20220031712 - Huang; Cai Gu ;   et al.
2022-02-03
Formulation Of Tocilizumab And Method For Treating Covid-19 By Inhalation
App 20210403550 - Huang; Cai Gu ;   et al.
2021-12-30
Pharmaceutical Formulation Containing Combination Of M3 Antagonist-beta-2 Agonist And Inhaled Corticosteroids
App 20210401855 - Huang; Cai Gu ;   et al.
2021-12-30
Biopharmaceutical Formulation Of Anti-pd-1, Anti-pd-l1, And Anti-vegfr Therapeutic Monoclonal Antibodies And Method For Treating Nsclc By Inhalation
App 20210403568 - Huang; Cai Gu ;   et al.
2021-12-30
Pharmaceutical Formulation Containing Active Metabolites Of Remdesivir Or Its Analog For Inhalation
App 20210393663 - Huang; Cai Gu ;   et al.
2021-12-23
Preparation Of A Pharmaceutical Composition Of Olodaterol, Tiotropium Bromide And Budesonide
App 20210393521 - Huang; Cai Gu ;   et al.
2021-12-23
Pharmaceutical Formulation Containing Glycopyrrolate And Indacaterol Maleate
App 20210386730 - Huang; Cai Gu ;   et al.
2021-12-16
Pharmaceutical Formulation Containing Umeclidinium Bromide And Vilanterol Trifenatate
App 20210378955 - Huang; Cai Gu ;   et al.
2021-12-09
Pharmaceutical Formulation Containing Remdesivir And Its Active Metabolites For Dry Powder Inhalation
App 20210353650 - Huang; Cai Gu ;   et al.
2021-11-18
Pharmaceutical Formulation Containing Active Metabolites Of Remdesivir For Inhalation
App 20210346288 - Huang; Cai Gu ;   et al.
2021-11-11
Inhalable Formulation of a Solution Containing Tiotropium Bromide
App 20210322310 - Huang; Cai Gu ;   et al.
2021-10-21
Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol
App 20210322311 - Huang; Cai Gu ;   et al.
2021-10-21
Inhalable Formulation of a Solution Containing Olodaterol
App 20210322309 - Huang; Cai Gu ;   et al.
2021-10-21
Inhalable Formulation Of A Solution Containing Levalbuterol Tartrate
App 20210290568 - Huang; Cai Gu ;   et al.
2021-09-23
Inhalable Formulation of a Solution Containing Glycopyrronium Bromide
App 20210275449 - Huang; Cai Gu ;   et al.
2021-09-09
Pharmaceutical Formulation Containing Remdesivir
App 20210252027 - Huang; Cai Gu ;   et al.
2021-08-19
Liposome formulation of vilanterol trifenatate
Grant 11,083,693 - Huang , et al. August 10, 2
2021-08-10
Liposome Formulation Of Vilanterol Trifenatate
App 20210220275 - Huang; Cai Gu ;   et al.
2021-07-22
Inhalable Formulation Of A Solution Containing Glycopyrrolate And Olodaterol Hydrochloride
App 20210220367 - Huang; Cai Gu ;   et al.
2021-07-22
Propellant-free Formulation For Inhalation
App 20210205223 - Huang; Cai Gu ;   et al.
2021-07-08
Liposome Formulation of Fluticasone Furoate and Method of Preparation
App 20210059937 - Huang; Cai Gu ;   et al.
2021-03-04
Formulation Of Antibody Based Drugs For Treating Lung Cancer By Inhalation
App 20210030868 - Huang; Cai Gu ;   et al.
2021-02-04
Cartridge With Single-layer Container And Its Nozzle-shaped Cap For Nebulization Inhalation
App 20210030978 - Huang; Cai Gu ;   et al.
2021-02-04
Inhalable Formulation Of A Solution Containing Formoterol Fumarate And Aclidinium Bromide
App 20200405700 - Huang; Cai Gu ;   et al.
2020-12-31
Inhalable Formulation Of A Solution Containing Indacaterol Maleate And Glycopyrronium Bromide
App 20200375945 - Huang; Cai Gu ;   et al.
2020-12-03
Inhalable Formulation Of A Solution Containing Vilanterol Trifenatate And Umeclidinium Bromide
App 20200368214 - Huang; Cai Gu ;   et al.
2020-11-26
Inhalation Device for Administering Powdered Pharmaceutical Composition
App 20200324064 - Huang; Cai Gu ;   et al.
2020-10-15
Inhalation Atomizer Comprising a Blocking Function and a Counter
App 20190030268 - Huang; Cai Gu
2019-01-31
Inhaler Device for Administering Powered Pharmaceutical Compositions via Inhalation
App 20180344956 - HUANG; CAI GU ;   et al.
2018-12-06
Formulations, Salts And Polymorphs Of Transnorsertraline And Uses Thereof
App 20180071230 - Laughlin; Sharon M. ;   et al.
2018-03-15
Coated tablets of eszopiclone
Grant 9,114,086 - Hsia , et al. August 25, 2
2015-08-25
Formulations, Salts And Polymorphs Of Transnorsertraline And Uses Thereof
App 20150196502 - LAUGHLIN; Sharon M. ;   et al.
2015-07-16
Formulations, salts and polymorphs of transnorsertraline and uses thereof
Grant 8,957,114 - Laughlin , et al. February 17, 2
2015-02-17
Coated Tablets Of Eszopiclone
App 20140271858 - HSIA; Richard ;   et al.
2014-09-18
Formulations, Salts And Polymorphs Of Transnorsertraline And Uses Thereof
App 20130116332 - Laughlin; Sharon M. ;   et al.
2013-05-09
Crystalline polymorphs of desvenlafaxine succinate and their preparations
Grant 7,820,716 - Huang , et al. October 26, 2
2010-10-26
Coated Tablets Of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-- Dihydro-5H-Pyrrolo[3,4-b]Pyrazine And Methods For Measuring Effectiveness Of Coating
App 20100221338 - Hsia; Richard ;   et al.
2010-09-02
Crystalline polymorph of sitagliptin phosphate and its preparation
App 20090247532 - Huang; Cai Gu ;   et al.
2009-10-01
Preparations of new polymorphic forms of varenicline tartrate
App 20090215787 - Huang; Cai Gu ;   et al.
2009-08-27
Crystalline polymorphs of desvenlafaxine succinate and their preparations
App 20080188567 - Huang; Cai Gu ;   et al.
2008-08-07
Stable pharmaceutical formulation comprising atorvastatin calcium
App 20080038332 - Huang; Cai Gu ;   et al.
2008-02-14
Preparation of crystalline polymorphs of rimonabant hydrochloride
App 20080004313 - Huang; Hui Min He ;   et al.
2008-01-03

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed